ミネソタ州における膠腫の臨床試験
ミネソタ州内の拠点で、膠腫に関する13件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease
- Mayo Clinic in Rochester, Rochester
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07025226A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/10/01更新 · NCT05099003SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Mayo Clinic - Rochester, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Children's Minnesota, Minneapolis
被験者募集中第1相
1歳〜25歳 · 全性別 · 2026/08/18更新 · NCT04485559Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions
- Mayo Clinic in Rochester, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/08/18更新 · NCT04047264A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
- Mayo Clinic in Rochester, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/08/10更新 · NCT07074756A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- St. Luke's Hospital, Duluth
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
- Mayo Clinic in Rochester, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/24更新 · NCT07468136Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
- Mayo Clinic, Rochester
被験者募集中第1/2相
19歳以上 · 全性別 · 2026/06/08更新 · NCT06011109Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Mayo Clinic Cancer Center, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
- Mayo Clinic in Rochester, Rochester
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/03/24更新 · NCT06482905Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
- Mayo Clinic in Rochester, Rochester
被験者募集中早期第1相
18歳以上 · 全性別 · 2025/11/04更新 · NCT05717153CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
- Children's Minnesota, Minneapolis
被験者募集中第1相
2歳〜25歳 · 全性別 · 2024/03/12更新 · NCT06305910ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。